Deep Yellow Limited (ASX:DYL) Faces Fifth Legal Challenge in Namibia
Deep Yellow Limited (ASX:DYL) faces a fifth legal challenge in Namibia over mining license ML237, seeking to annul its environmental clearance.
Tag: Regulatory News & Compliance
Novonix Limited (ASX:NVX) Responds to ASX Inquiry on Production Delay
Novonix Limited (ASX:NVX) responds to ASX inquiry, stating production delay for Panasonic Energy supply agreement is not material to its securities’ value.
Dart Mining NL (ASX:DTM) Announces Trading Halt
Dart Mining NL (ASX:DTM) requests a trading halt pending a capital raise announcement, effective until 24 Feb 2025 or sooner.
Healius Limited (ASX:HLS) Releases Independent Auditor’s Review Report
Healius Limited (ASX:HLS) releases an independent auditor’s review confirming compliance with key regulations and accounting standards.
SkyCity Entertainment Group Limited (ASX:SKC) Releases 1H25 Financial Results
SkyCity Entertainment Group Limited (ASX:SKC) reports a 5% revenue decline and a 22% drop in EBITDA for the first half of 2025, revising its FY25 outlook.
Mayur Resources Limited (ASX:MRL) Announces A$80 Million Equity Raising
Mayur Resources Limited (ASX:MRL) announces an A$80 million equity placement to fund the expansion of its Central Lime Project and enhance working capital.
Field Solutions Holdings Limited (ASX:FSG) Continues Suspension from Quotation
ASX continues suspension of Field Solutions Holdings Limited (ASX:FSG) securities due to inadequate financial condition.
Kaili Resources Limited (ASX:KLR) Selects Drill Sites for Rare Earths Exploration
Kaili Resources Limited (ASX:KLR) selects drill sites for rare earths exploration in South Australia, planning shallow drilling and seeking regulatory approvals.
Poseidon Nickel Limited (ASX:POS) Completes Merger with Horizon Minerals
Poseidon Nickel Limited (ASX:POS) and Horizon Minerals complete their merger through approved schemes of arrangement, leading to Poseidon’s delisting.
Neuren Pharmaceuticals (ASX:NEU) Receives FDA Fast Track for NNZ-2591 in Pitt Hopkins Syndrome
Neuren Pharmaceuticals (ASX:NEU) gains FDA Fast Track designation for NNZ-2591 to treat Pitt Hopkins syndrome, following successful Phase 2 trial.